Stockscreener 앱 받기
0.0775
6.63%
-0.0055
시간 외 거래:
.08
0.0025
+3.23%
전일 마감가:
$0.083
열려 있는:
$0.083
하루 거래량:
25.78M
Relative Volume:
1.72
시가총액:
$20.54M
수익:
$175.04M
순이익/손실:
$-44.52M
주가수익비율:
-0.4306
EPS:
-0.18
순현금흐름:
$-56.05M
1주 성능:
-3.00%
1개월 성능:
-69.37%
6개월 성능:
-87.50%
1년 성능:
-92.15%
1일 변동 폭
$0.0745
$0.083
1주일 범위
$0.071
$0.12
52주 변동 폭
$0.071
$1.33
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
명칭
Adaptimmune Therapeutics Plc Adr
전화
44 1235 430000
주소
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.0775 | 21.28M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-06-26 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-07-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-09 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-05-28 | 개시 | Barclays | Underweight |
| 2020-04-22 | 개시 | Mizuho | Neutral |
| 2019-08-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-05-31 | 개시 | ROTH Capital | Buy |
| 2019-05-30 | 재개 | Citigroup | Buy |
| 2019-05-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | 개시 | Wells Fargo | Market Perform |
| 2016-10-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | 개시 | Raymond James | Outperform |
| 2016-02-25 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | BofA/Merrill | Neutral |
| 2015-06-01 | 개시 | Guggenheim | Buy |
| 2015-06-01 | 개시 | Leerink Partners | Outperform |
모두보기
Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m By Investing.com - Investing.com India
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Let’s Jump Into The Geron Corp (NASDAQ: GERN) Stock Forecast - Marketing Sentinel
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics Plc ADR (ADAP)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
Adaptimmune Therapeutics Plc Adr (ADAP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):